The pharmaceutical company has received the second tranche of a $91m series D round backed by companies including GE, Ipsen and Nordic Bioscience.
US-based pharmaceutical company Radius Health closed the second of an already secured three tranche funding round on Wednesday, worth $27.7m. Radius has now received $57.3m out of a $91m total for the round.
Included in the $27.7m figure was $6.2m in debt financing provided by GE Capital’s Healthcare Financial Services, a corporate venturing unit attached to industrial conglomerate General Electric, and medical-focused financial services firm Oxford Finance.
Radius did not disclose the specific identity of any additional backers in the…
